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Free fatty acid metabolism
Metabolomics
Mass spectrometryIngestion of very low-carbohydrate ketogenic diets (KD) is associated with weight loss, lowering of glucose and
insulin levels and improved systemic insulin sensitivity. However, the beneﬁcial effects of long-term feeding
have been the subject of debate. We therefore studied the effects of lifelong consumption of this diet in mice.
Complete metabolic analyses were performed after 8 and 80 weeks on the diet. In addition we performed a
serum metabolomic analysis and examined hepatic gene expression. Lifelong consumption of KD had no effect
on morbidity or mortality (KD vs. Chow, 676 vs. 630 days) despite hepatic steatosis and inﬂammation in KD
mice. The KD fed mice lost weight initially as previously reported (Kennnedy et al., 2007) and remained lighter
and had less fatmass; KD consumingmice had higher levels of energy expenditure, improved glucose homeosta-
sis and higher circulating levels of β-hydroxybutyrate and triglycerides than chow-fed controls. Hepatic expres-
sion of the critical metabolic regulators including ﬁbroblast growth factor 21 were also higher in KD-fed mice
while expression levels of lipogenic enzymes such as stearoyl-CoA desaturase-1was reduced.Metabolomic anal-
ysis revealed compensatory changes in amino acidmetabolism, primarily involving down-regulation of catabolic
processes, demonstrating that mice eating KD can shift amino acid metabolism to conserve amino acid levels.
Long-term KD feeding caused profound and persistent metabolic changes, the majority of which are seen as
health promoting, and had no adverse effects on survival in mice.
© 2015 Published by Elsevier B.V.1. Introduction
Ketogenic diets are of interest because in humans, they have been
used for weight loss [2,3], and are also used to treat refractory epilepsy,
particularly in pediatric populations [4,5]. Studies of KD have been ex-
tended to mice in an attempt to identify potential mediators of their
metabolic effects. Despite the high-fat content of the diet, mice fed KD
fail to gain excess weight and develop a unique metabolic state charac-
terized by increased energy expenditure, increased systemic insulin
sensitivity, and a distinct hepatic pattern of gene expression. Consump-
tion of KD is also effective in inducing weight loss in wild-type mice
with diet-induced obesity, as well as improving glucose tolerance with-
out weight loss in the ob/ob mouse [1,6,7]. Additional studies demon-
strated that diabetic nephropathy can be reversed through the use of
KD intervention in both Type 1 (Akita) and Type 2 (db/db) mouse
models [8]. These results show promise for the therapeutic use of KD;Beth Israel Deaconess Medical
MA 02215, USA.
atos-Flier).yet there is controversy regarding the potential adverse long term con-
sequences. One study suggests that chronic KD consumption leads to
pathological hepatic steatosis as well as insulin resistance and glucose
intolerance [9,10]. However, to date the longest duration of a study of
mice eating KD has been 12 weeks [10]. Since human consumption of
KD for weight loss or refractory epilepsy can continue for months or
years, the long-term health and lifetime effects of this dietary state are
of clinical importance.
To fully understand the long-term physiologic consequences of KD
on systemic health, longevity, and metabolism, we compared both the
short-term effects of 8 weeks of KD (STKD) versus consuming a
standard mouse “chow” diet, (STCH) and long-term effects after 66–
80 weeks on the diets (LTCH and LTKD for chow and KD respectively).
We compared physiologic parameters, gene expression proﬁles, and
serum metabolomic proﬁles of each of the four cohorts. We found that
the previously reported increase in energy expenditure and insulin sen-
sitivity [1] persisted for over a year.Wealso compared changes in amino
acid metabolism in mice fed the diet for 8 weeks to changes in mice fed
the diet for 80 weeks. In both STKD and LTKD cohorts we found differ-
ences in amino acid metabolism as assessed both by metabolomics
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catabolism. We also found increases in markers of oxidative stress, and
inﬂammation in the liver in both STKD and LTKDmice. As there was no
premature mortality over duration of the study, which continued until
the death of the lastmouse in the longevity cohort, we found no adverse
effects of KD on life span. Thus we demonstrate that ketogenic diets are
well tolerated over the lifespan of the animal, that animalsmaintain im-
proved glucose homeostasis, and that the mice develop sustained com-
pensatory changes in amino acid metabolismwhichmay allow them to
compensate for decreases in dietary protein intake and de novo amino
acid biosynthesis.
2. Materials and methods
2.1. Animals
Animals were obtained from The Jackson Laboratory (C57Bl6J,
000664) in Bar Harbor, ME and maintained at 24 °C on a 12:12-h light-
dark cycle. Animals were allowed ad libitum access to food, except
where stated otherwise. All procedures were in accordance with NIH
Guidelines for the Care and Use of Animals and were approved by the
Beth Israel Deaconess Medical Center Institutional Animal Care and Use
Committee (IACUC). C57BL/6J mice were split into two groups at
8 weeks of age and fed standard chow or KD ad libitum. Within dietary
groups, subsets of mice were randomly selected for physiologic tests or
terminal harvest for tissue analysis. Physiologic tests included nuclear
magnetic resonance (qNMR), indirect calorimetry, glucose tolerance test
(GTT), and insulin tolerance test (ITT). Mice selected for tissue analysis
and harvested at 16 weeks for the short-term study and 88 ± 1 week
for the long-term study.
2.2. Diet studies
LabDiet 5008 (Pharmaserv, Framingham, MA) consisting of 6.5% fat,
23.5% protein, and 56% carbohydrate (2.5% sucrose) wt/wt was used as
standard chow. The ketogenic diet (KD) was obtained from Bio-Serv
(F3666, Frenchtown, NJ) and consisted of 78.9% fat, 9.5% protein, and
0.76% carbohydrate (0% sucrose) wt/wt. This formulation has been
demonstrated to induce ketosis in rodents [11] and used by us in previ-
ous studies [1]. The macronutrient-calorie percent composition from
each diet was as follows: standard chow: 16.7% fat, 26.8% protein, and
56.4% carbohydrate (6.5% sucrose); KD: 95% fat, 0% carbohydrate (0%
sucrose), and 5% protein.
2.3. Glucose and insulin tolerance tests
Glucose tolerance test: mice on standard chow (CH) and KD were
fasted for 16 h before an intraperitoneal (ip) injection D-glucose
(2 g/kg body weight; Sigma, St. Louis, MO) was administered 4 h after
light onset. Tail blood glucose levels were measured using a OneTouch
Ultra glucometer (Lifescan, Milpitas, CA). To assess insulin tolerance, 7
CH and 5 KD ad libitum-fed-mice were injected ip, with insulin
(0.75 U/kg) 8 h after onset of the light cycle (Lilly, Indianapolis, IN).
2.4. Indirect calorimetry
Mouse energy expenditure was measured by indirect calorimetry
using the Comprehensive Lab AnimalMonitoring System (Columbus In-
struments, Columbus, OH). Mice fed chow for 60 weeks were housed
singly with ad libitum access to food andwater. Analysis was performed
at 24 °C under a 12:12-h light-dark cycle (light period 0600–1800).
Mice were acclimated in the metabolic chambers for 48 h before
collecting measurements used for data analysis. Ambulatory activity,
oxygen consumption, and carbon dioxide production were simulta-
neously determined.2.5. Body composition analysis
Body composition, including lean and fat mass, was assessed using
an EchoMRI 3-in-1 quantitative nuclear magnetic resonance (qNMR)
system (Echo Medical Systems, Houston, TX). This test is performed in
conscious mice that are immobilized for one minute.2.6. Quantitative RT-PCR
Ribonucleic acid (RNA) was isolated from tissue ﬂash-frozen in liq-
uid nitrogen using an RNAeasy Lipid mini kit (Qiagen, Germantown,
MD) according to manufacturer's instructions. A DNase (Qiagen, Ger-
mantown, MD) step to digest the genomic DNA was included. Comple-
mentary DNA (cDNA) was made from isolated RNA using oligo(dt) and
randomhexamer primers and reverse transcriptase (QuantiTech RT Kit;
Qiagen, Germantown, MD). Quantitative PCR was performed using the
7800HT (Applied Biosystems, Foster City, CA) thermal cycler and SYBR
Green master mix (Applied Biosystems, Foster City, CA). Relative
mRNA abundancewas calculated and normalized to levels of the house-
keeping gene 36B4. Primers are included in Supplementary Table 1.2.7. Survival analysis
C57BL/6J mice were split into two groups at 8 weeks of age and
allowed ad libitum access to either standard chow or KD. The Kaplan–
Meier survival curve was created with the log-rank test equal to the
Mantel–Haenszel test. All statistical analyses were performed with
GraphPad Prism v6.04 for Windows (GraphPad Software, San Diego,
California, USA).2.8. Serum and liver assays
Serum FGF21 concentrations were measured using Quantikine
mouse FGF21 enzyme-linked immunosorbent assay (ELISA) (R&D Sys-
tems, Minneapolis, MN), nonesteriﬁed free fatty acids (NEFAs) (NEFA C
colorimetric assay; Wake Chemicals, Richmond, VA), triglycerides (Tri-
glyceride Colorimetric Assay; Stanbio Laboratory, Boerne, TX), β-
hydroxybutyrate (β-hydroxybutyrate colorimetric assay, Stanbio Labo-
ratory), cholesterol (Cholesterol Liquicolor, colorimetric assay; Stanbio
Laboratory), insulin (ultra-sensitive mouse insulin ELISA; Crystal Chem,
Chicago, IL), and alanine aminotransferase (ALT Colorimetric Assay,
Pointe Scientiﬁc, Canton, MI). For tissue cholesterol and triglyceride as-
says, a Folch extraction was ﬁrst performed on 100 mg of frozen tissue
[12] before colorimetric analysis (Cholesterol Liquicolor, colorimetric
assay; Stanbio Laboratory), (Triglyceride Colorimetric assay; Stanbio
Laboratory, Boerne, TX).2.9. Targeted mass spectrometry and metabolomics
Serum (100 μL)was collected and isolated frommice 16weeks (STCH
and STKD) and 88 weeks (LTCH and LTKD) of age. Serum samples were
extracted at dry ice temperatures using a 1:4 ratio of serum:methanol
resulting in a total volume of 80% methanol. Samples were centrifuged
and resulting supernatant was dried under vacuum. Samples were re-
suspended using 20 μL high-performance liquid chromatography
(HPLC) grade water for mass spectrometry and 10 μL was injected and
analyzed using a 5500 QTRAP triple quadrupole mass spectrometer
(AB/Sciex) coupled to a Prominence UFLC HPLC system (Shimadzu) via
selected reaction monitoring (SRM) of a total of 249 endogenous water
soluble metabolites as previously described [13]. All mass spectrometry
data were collected and processed as previous reported [13]. Data are
presented as mean ± SEM. Comparisons between two groups were per-
formed using an unpaired t test.
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Data are presented as mean ± SEM. Comparisons between two
groupswere performedusing anunpaired t test, while for 4-group com-
parisons a two-way ANOVA utilized where appropriate, the effects of
duration and diet were queried and post-hoc comparisons were deter-
mined by Sidak's post-hoc test for individual time point analysis.3. Results
3.1. KD-fed mice remain leaner and lighter than WT controls
To evaluate the effects of chronic feeding of KD we generated a co-
hort of mice that were fed KD for 8 weeks (designated short term or
STKD) as a baseline group for comparison. In this cohort we reproduced
our previous reported ﬁndings [1]. Mice fed KD initially loseweight dra-
matically; however, after 18 weeks their weight returns to the baseline
and the animals gradually accumulate mass. Over a 40-week period,
chow-fed mice gained 16 g (1.6 g/month), while the KD-fed mice
gained only 1.2 g over the same period (0.12 g/month) (Fig. 1A). Body
composition analysis revealed that the weight differential results from
both a lower lean mass (Fig. 1B) and fat mass in KD compared to
chow fed animals (Fig. 1C). As a percent of total mass, the lean mass
of the KD-fed mice is greater (Fig. 1D) than that of chow-fed controls
(Fig. 1E), indicating that relative leanmasswaspreserved. Indeed, tissue
weights after 80-weeks on KD revealed that the relative mass of the
liver, brown fat and epididymal fatwas the same in KD and chow fed an-
imals (Supplemental Fig. 1). Together, these ﬁndings show that long-
term administration of KD maintains a lean phenotype.Fig. 1. Ketogenic diet fed mice remain lighter and leaner than chow fed controls and have sim
baseline, but remain lighter than chow-fed controls (effect of diet P b 0.0001). The values repres
curvewas determinedwith two-wayANOVA. Both leanmass (B) and fat (C)mass are reduced in
for bodymass (D& E), KD-fedmice have a greater percentage of leanmass (effect of diet P b 0.00
CH, n= 6–13 per time point, KD, n= 8–11 per time point. Signiﬁcance in body composition w
analysis, signiﬁcance is designated by asterisks with *P b 0.05, **P b 0.01, ***P b 0.001, and ****P
ation inmorbidity ormortality in KD fedmice compared to CH fedmice (F). Comparison of surv
study contained CH n= 40, KD n= 31.Given the dramatic difference in nutrient availability of the two
diets, we postulated that chronic consumption of KD could inﬂuence
the morbidity or mortality. We therefore conducted a survival study
and found that lifelong consumption of KD had no inﬂuence upon sur-
vival including no major morbidity when compared to chow (Fig. 1F).
Despite profound systemic metabolic and physiologic changes in mice,
including increases in metabolic rate and altered glucose homeostasis,
KD was not shown to alter survival curves, although median survival
was slightly longer on KD (676 days compared to 630 days for chow).
3.2. LTKD-fed mice demonstrated increased energy expenditure and loss of
a diurnal rhythm in RER
We have previously shown that short-term consumption of KD is as-
sociated with increased energy expenditure. To assess the persistence of
this effect, we performed indirect calorimetry at 60 weeks. We found
that mice fed KD exhibited greater oxygen consumption (VO2) than
chow-fed cohorts (Fig. 2A) (p = 0.003, Repeat Measures ANOVA).
Furthermore, in short term KD fed animals there was a loss of diurnal
pattern of the respiratory exchange ratio (RER), which indicated contin-
uous use of fatty acids as an energy substrate (Fig. 2B). Although the KD-
fed mice were smaller, they generated the same heat as larger mice on
chow(Fig. 2C). Combined, these results demonstrate that long-term con-
sumption of KD sustains increases in energy expenditure.
3.3. LTKD-feeding improved glucose tolerance and enhanced insulin
sensitivity
As seen in STKD, LTKD-fed animalsmaintained glucose tolerance and
exhibited improved insulin sensitivity, based on several parameters.ilar life expectancy. KD fed mice initially lose weight (A) and after a few months return to
ent groupmeans (±SEM, initial group size CH, n=48; KD, n=39). Signiﬁcance inweight
KD fedmice compared to chow fed counterparts asmeasured byMRI, butwhen corrected
01) and less fatmass (effect of diet P=0.0002). The values represent groupmeans±SEM,
as determined with two-way ANOVA with Sidak's post-hoc test for individual time point
b 0.0001. Survival analysis in animals fed chow or KD demonstrating no signiﬁcant alter-
ival curveswas conductedwith a log-rank (Mantel–Cox) test, P= 0.9092. Starting survival
Fig. 2.Mice fed KD for 60weeks have sustained changes inmetabolic rate and glucose homeostasis. KD-fedmice have a highermetabolic rate of VO2 consumption (A). The cyclic nature of
the respiratory exchange rate (RER) is lost in the KD-fed mice (B) due to constant utilization of lipid as a fuel source. An indirect measure of heat (C) trends higher in the KD mice. The
values for VO2 consumption, RER and heat all represent group means (±SEM, group size CH, n= 8; KD, n= 7). Mice fed KD for 60 weeks maintain glucose tolerance as measured by
an IP glucose tolerance test (D). The values represent groupmeans (±SEM, group size CH, n=8; KD, n=7). Mice fed KD for 60weeks remain insulin-sensitive as shown by an ITT either
by glucose level (E) or %change (F). The values represent group means (±SEM, group size CH, n=7; KD, n=5). Two-way Repeat Measures ANOVA for all datasets in this ﬁgure, signif-
icance is designated by asterisks with *P b 0.05, **P b 0.01, ***P b 0.001, and ****P b 0.0001.
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glucose tolerant (Fig. 2D) (p b 0.05 RM ANOVA). Additionally, LTKD fed
mice had dramatically lower baseline insulin levels than LTCH fed mice
(LTCH = 4.01 ng/ml, LTKD = 0.41 ng/ml, Student's t-test p b 0.01).
Mice on LTKD also showed a more robust glucose lowering response to
exogenous insulin. Upon insulin administration, the lowest glucose
level achieved in chow fed mice was 105 mg/dl compared to 37 mg/dl
in LTKD. Furthermore, hypoglycemia persisted for a longer period.
While glucose levels returned to the baseline by 75 min in chow fed an-
imals, glucose levelswere still low at 90min in LTKD animals. Thus, LTKD
mice demonstrated enhanced insulin sensitivity as determined by an in-
sulin tolerance test (ITT) (Fig. 2E & F).3.4. Metabolic proﬁle
KD feeding led to a ﬁve-fold increase inβ-hydroxybutyrate levels, an
effect noted at 8 weeks, which persisted at 22 months demonstrating a
signiﬁcant effect of KD (Two-way ANOVA, P b 0.0001) (Fig. 3A). Circu-
lating levels of nonessential fatty acid (NEFA) levels were the same in
STCH and STKD fed animals. Interestingly, NEFAs rose in both the
LTCH and LTKD fed animals, demonstrating a signiﬁcant effect of age
(Two-way ANOVA, P = 0.0005) (Fig. 3B). Serum levels of cholesterol
were higher in mice fed KD (Two-way ANOVA, P = 0.0087) (Fig. 3C).
Triglyceride levels were higher in LTCH mice and LTKD mice, demon-
strating an age or “duration” effect (Two-way ANOVA, P = 0.0002)
(Fig. 3D). Analysis of hepatic cholesterol and triglycerides demonstrated
increased concentrations of these lipids in all KD-fed mice (Two-way
ANOVA, effect of diet P = 0.0378 CHOL and P = 0.0075 TG) (Fig. 3E
and F). Together, these results show that hepatic lipids increase upon
KD feeding; however, long-term KD feeding has no additive effects
upon the increased levels seen short-term.3.5. KD-fed mice have altered expression of critical hepatic regulators of
metabolism, genes involved in fatty acid oxidation, ketogenesis and fatty
acid transport
Several reports note that KD feeding leads to altered expression of
genes involved in energy balance [1,6,10,14]. Consistent with these
studies, we found that the expression of uncoupling protein 2 (UCP2),
ﬁbroblast growth factor 21 (FGF21), and peroxisome proliferator-
activated receptor gamma (PPARγ) were all elevated under STKD feed-
ing. These changes persisted with LTKD feeding (Fig. 4A). Decreased ex-
pression of gene encoding rate-limiting enzymes of de novo lipogenesis
and triglyceride synthesis was observed (Fig. 4B), while increases in
fatty acid oxidation and ketogenesis (Fig. 4C & D) gene expression
were all largely attributable to KD alone. Given previous ﬁndings of
hepatic steatosis in STKD mice [1,10], we examined markers of inﬂam-
mation and ﬁbrosis. We found that KD consumption caused increases
in the expression of chemokines/cytokines or genes related to pro-
inﬂammatory pathways (Fig. 4E) and these too were principally as-
cribed to diet. The serum marker of liver injury, alanine transaminase
(ALT), was also elevated in all KD fed mice, and in the LTCH fed mice
(P b 0.01) (Fig. 4F). Interestingly, the effects of age and feeding on ALT
expression were not cumulative; there were no exaggerated effects of
LTKD feeding compared to LTCH feeding. Together, these ﬁndings sug-
gest that many of the effects previously observed during STKD feeding
persist in LTKD.3.6. Metabolic proﬁling identiﬁes a long-term compensatory amino acid
metabolism in response to KD
The differences in systemic metabolism suggested that KD-fed mice
would have a distinctmetabolic proﬁle. To study the associated changes
Fig. 3. Serum nutrient proﬁles and liver lipids for short or long-term feeding of chow and
KD. Data is shown asmeans± SEM and is shown for serum (A–D) or for liver (E–F). Two-
way ANOVA with Sidak's post-hoc test for individual time point analysis, signiﬁcance
(P b 0.05) is designated by letters: asigniﬁcantly different from STCH; bsigniﬁcantly differ-
ent from LTCH; csigniﬁcantly different from STKD; dsigniﬁcant effect of diet; and
esigniﬁcant effect of age. n= 4–9 per group.
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bolomics platform to proﬁle polar metabolites present in the serum of
our four cohorts. We carried out several unbiased forms of classiﬁcation
to identify metabolic signatures that distinguished chow-versus KD-fed
mice. We detected 217 and 239 metabolites in the short term and long
term cohorts respectively (Supplemental Files 1 and 2). Of these morethan 125metabolites were used for analysis which identiﬁedmetabolic
signatures unique to KD-fed mice compared to chow-fed mice, shown
here in an unsupervised hierarchical clustering of serum metabolite
proﬁles (Fig. 5A). This clustering revealed a distinct pattern of metabo-
lites differentially (either elevated or decreased) in the sera of KD-fed
mice relative to chow-fed mice (Fig. 5A and Supplemental Fig. 2A, B
for short term and Supplemental Fig. 3A, B for long term). The tree
structure obtained from clustering each durational cohort exhibits
two distinct subclusters corresponding to the two different diets (Sup-
plemental Fig. 4A, B). We then performed a principal component anal-
ysis (PCA) to determine the speciﬁc metabolites characteristic of these
diet-dependent signatures (Fig. 5C, D). The analysis revealed that the
ﬁrst principal component was of sufﬁcient magnitude to distinguish
KD and chow-fed animals. To further identify the speciﬁc pathways in-
volved in response to KD, we used the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database to group the most signiﬁcant metabolites
changing between the four cohorts (Fig. 5E). The pathway analysis re-
vealed overlap in pathways that altered by both short and long termKD.
KEGG analysis summarized discriminant metabolites between the
four cohorts. By comparing both ST cohorts, we found that short-term
effects of KD led to alterations in the metabolic signatures associated
with pathways for glutamate metabolism, protein biosynthesis, mito-
chondrial electron transport chain, the ammonia cycle and the tricar-
boxylic acid cycle. By comparing both KD cohorts, we found that the
KD over time led to alterations in metabolic signatures associated with
pathways for arginine and prolinemetabolism, glycine, serine and thre-
onine metabolism, glycolysis/gluconeogenesis, aspartate metabolism,
nicotinate and nicotinamidemetabolism, the urea cycle andmethionine
metabolism. Interestingly, although circulating methionine levels were
not signiﬁcantly changed, the intermediate metabolite homocysteine
was increased in both STKD and LTKD.
Examples of some pathway-wide metabolic changes used in the
pathway analysis are depicted in Fig. 6, demonstrating that critical met-
abolic networks are susceptible to diet-induced changes under KD. These
changes include increases in critical intermediates of the tricarboxylic
acid cycle (TCA cycle), β-oxidation, and ketogenesis. Metabolomic anal-
ysis revealed a large increase in the ketone body acetoacetate in both
short-term and long-term fed KD groups, compared to their respective
chow-fed controls (Fig. 6A). These data, combined with the direct
serum measurement of β-hydroxybutyrate (Fig. 3A), are consistent
with the extreme state of ketosis in the KD-fed mice. Gene expression
analysis revealed increased hepatic expression of genes involved in β-
oxidation (Fig. 4A, B). Serum concentrations of β-oxidation intermedi-
ates carnitine and acylcarnitine were paradoxically decreased in STKD
mice, indicating a possible dissociation between hepatic gene expression
and serum content of oxidative markers (Fig. 6A).
KD alters the normal TCA cycle as STKD fed mice up-regulated
isocitrate, α-ketoglutarate, succinate, fumarate, oxaloacetate, and cit-
rate compared to the chow fed controls (Fig. 6A). Another pathway
that changed when comparing chow and KD involved tryptophan me-
tabolism including reduced circulating tryptophan and increased down-
stream metabolites kynurenic acid, quinolinic acid and nicotinamide
alongwith decreased gene expression of the enzyme Aminocarboxymu-
conate Semialdehyde Decarboxylase (ACMSD) (Fig. 6B). Analysis of the
TCA cycle and tryptophanmetabolism in LTKD fedmice revealed a sim-
ilar pattern of expression (Supplemental Fig. 5A, B).
To further investigate the metabolic adaptations to the different
amino acid (AA) contents of the diets, we evaluated both the amount
of AA available in the two diets and the concentration of circulating
AA in the serum. In Fig. 7A, we plotted the quantity of AA found in the
KD as a percentage found in the chow, juxtaposed with the amount of
AA found in the serum of LTKD as a percentage of that found in the
serum of LTCH cohort. Two observations are notable: 1) the AA content
in the KD is extremely low and 2) there is a strikingmaintenance of cir-
culating AAmetabolites in KD-mouse serum.We postulate that AA star-
vation triggers the amino acid response (AAR), a reaction observed
Fig. 4. Hepatic gene expression: during short or long-term feeding of KD, critical metabolic regulators remain elevated (A) and de novo lipogenic/triglyceride synthesis-genes remain de-
pressed (B). With a few exceptions, expression in the liver of genes involved in fatty acid oxidation and ketogenesis elevate upon KD feeding and remain elevated long-term (C & D). KD
feeding and/or aging increases gene expression markers (E) and the serum marker aminotransferase (F) of hepatic inﬂammation and ﬁbrosis, but the increase is not cumulative. PPARγ,
peroxisome proliferator-activated receptor gamma; FGF21, ﬁbroblast growth factor 21; PGC1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; UCP2, uncoupling
protein 2, SCD-1, stearoyl-CoA desaturase-1; FAS, fatty acid synthase;DGAT2, diglyceride acyltransferase; SREBP1c, sterol regulatory element-binding transcription factor 1c; ACADM, acyl-
Coenzyme A dehydrogenase [medium chain]; ACADL, acyl-Coenzyme A dehydrogenase [long chain]; ACADVL, acyl-Coenzyme A dehydrogenase [very long chain]; Hmgcs2, 3-hydroxy-3-
methylgutaryl-CoA synthase 2 (mitochondrial); BDH1, 3-hydroxybutyrate dehydrogenase (type 1); HADH, hydroxyacyl-CoA dehydrogenase;MCP1, monocyte chemotactic protein-1;
Cd68, cluster of differentiation 68;Mmp2, matrix metalloproteinase-2; TIMP1, tissue inhibitor of metalloproteinase 1. Graphs are shown means ± SEM. Two-way ANOVA utilized on all
data sets, effects of duration and diet queried, post-hoc comparisons determined by Sidak's post-hoc test for individual time point analysis, signiﬁcance (P b 0.05) is designated by letters:
asigniﬁcantly different from STCH; bsigniﬁcantly different from LTCH; csigniﬁcantly different from STKD; dsigniﬁcant effect of diet; and esigniﬁcant effect of age. n= 4–9 per group.
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AA catabolic genes likely offsets the low concentration of protein sub-
strate in the diet [15]. We examined hepatic gene expression involved
in the AAR and found that activating transcription factors 3, 4, and 5
(ATF3-5), asparagine synthetase (ASNS), and tribbles homolog 3 (TRB3),
all markers of AAR [16–19], were increased in KD-fed mice (Fig. 7B).
We also examined hepatic AA catabolism genes (Fig. 7C). We found re-
duced expression of krüppel-like factor 15 (KLF15), a gene associated
with amino acid catabolism and a known regulator of alanine aminotrans-
ferase (ALT1), involved in pyruvatemetabolism, 4-hydroxyphenylpyruvate
dioxygenase (HPD) involved in tyrosinemetabolism, and proline dehydro-
genase 1 (Prodh), involved in proline degradation. There was also an in-
crease in branched chain ketoacid dehydrogenase kinase (Bckdk) which
catalyzes the phosphorylation and inactivation of the branched-chain
alpha-ketoacid dehydrogenase complex, the key regulatory enzyme of
the valine, leucine and isoleucine catabolic pathways. Proteomic analysisrevealed altered expression in the KD fedmice of all ﬁve of these keyme-
diators of AA.
4. Discussion
In mice, consumption of a ketogenic diet results in a unique physio-
logic state asmetabolism shifts from a glucose-based “economy” to one
that is fatty acid-based wherein oxidation of FFA results in the genera-
tion of ketones as the primary systemic fuel source. To understand the
long-term consequences of consumption of this very high-fat, low-
carbohydrate, low-protein diet, we assessed longevity and evaluated
the metabolic state of animals after 80 weeks on the diet. Although KD
is associated with fatty liver and inﬂammation [10], long-term con-
sumption of the diet appears to have no adverse health consequences
in mice as evidenced by normal life expectancy without observed
changes in morbidity and mortality. Animals eating KD maintain a
Fig. 5.Heatmaps depicting hierarchical clustering of CHvs. KDmetabolite composition.Unsupervised hierarchical clustering of serummetabolite proﬁles of STCHvs. STKD (A). Hierarchical
clustering of LTCHvs. LTKD serummetabolite composition (B) (gradient of red color formetabolites for relative positive correlation and green colors formetabolites negatively correlated).
Projection of individual samples onto theﬁrst twoprincipal components segregate into their respective groups of short-term chowvs. KD (C) or long-term chowvs. KD(D). Table depicting
a KEGG pathway analysis using metabolite fold change values for STCH vs. STKD and LTCH vs. LTKD (E). n= 5–9 per group.
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accelerates at around 40 weeks of age. KD-fed animals had improved
glucose homeostasis as assessed by glucose tolerance and systemic
insulin sensitivity at 60 weeks.
To better understand the metabolic adaptions to KD consumption
that permit normal long-term survival, we ﬁrst performed unsuper-
vised clustering analysis on serum metabolites. This revealed a distinct
metabolic signature in mice fed KD in comparison to mice fed standard
chow with major differences in pathways involving amino acid metab-
olism and speciﬁc metabolites associated with energetic processes. For
example, levels of substrates of the TCA cycle are generally higher in
mice consuming KD, reﬂecting differences in metabolic ﬂux in these es-
sential pathways. The KD that we use in our studies is a low protein diet
and supplies relatively low amounts of essential amino acids including
methionine and choline [20]. However, the levels of circulating amino
acids in the serum of KD-fed animals were largely maintained at levels
similar to that seen in chow-fed mice; although valine and tryptophan
concentrationswere depressed on the diet. There is a complex relation-
ship between glucose homeostasis and circulating levels of a subset ofamino acids. A report in humans demonstrated signiﬁcant associations
linking increased concentrations of the branched chain amino acids
(BCAAs) leucine, isoleucine, valine and the aromatic amino acids phe-
nylalanine (Phe) and tyrosine (Tyr) with a predisposition to diabetes
[21]. Other work showed an association between insulin resistance
and metabolites including BCAAs, Phe, Tyr and products of amino acid
catabolism [22,23]. Indeed, providing a Leu-depleted diet tomice result-
ed in increased insulin sensitivity [24]. Interestingly, FGF21 production
is stimulated upon Leu-deprivation [25]. However, the Leu effect may
be complex as doubling dietary Leu intake via Leu-containingwater im-
proved glucose homeostasis including insulin sensitivity in a mouse
model [26]. Circulating levels of branched chain amino acids per se
may not be critical for insulin sensitivity, as our KD mice were insulin
sensitive and yet maintained relatively normal circulating levels of
BCAA. Rather, reduced amino acid catabolismmight affect insulin sensi-
tivity through inﬂuences on insulin-sensitizing pathways. Indeed, we
found that KD-fed mice demonstrated decreased hepatic expression of
genes responsible for amino acid catabolism including BCAA catabolism.
For example, we found altered expression of Bckdk (Fig. 7), a kinase that
Fig. 6. Pathway depiction ofmetabolites alteredwith STCH or STKD feeding. Critical metabolic intermediates in BCAAmetabolism, the citric acid cycle, ketogenesis, β-oxidation, and tryp-
tophan catabolism pathways are shown. Chow values are normalized to “1”. The graph depicting Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) denotes gene expression.
Data is shown as means ± SEM. Asterisks designate signiﬁcance by Student's t-test. *P b 0.05, **P b 0.01, ***P b 0.001, ****P b 0.0001. n= 8 per group.
2063N. Douris et al. / Biochimica et Biophysica Acta 1852 (2015) 2056–2065catalyzes the phosphorylation and inactivation of the branched-chain
alpha-ketoacid dehydrogenase complex and is a key regulator of the
BCAA catabolic pathways.
With respect to speciﬁc amino acids, we noticed that KD changes
several metabolites of the tryptophan-NAD pathway. KD feeding de-
creased tryptophan levels while downstream metabolites quinolinic
acid and nicotinamide are increased. This metabolite pattern suggests
a shift at the branch point of tryptophanmetabolism towards NAD syn-
thesis as opposed to complete oxidation. The enzyme ACMSD plays a
key role in this pathway as increased expression reduces quinolinic
acid levels. We found that ACMSD is suppressed in KD resulting in in-
creased quinolinic acid levels and increased nicotinamide. This is consis-
tent with what is known about PPARα activation by KD consumption
[27] as well as the fact that PPARα activation suppresses the enzyme
ACMSD, which causes the ﬂux of tryptophan metabolites towards
NAD synthesis [28–30].
Although the compensatory responses to low protein content in KD
preserved circulating amino acid levels, we nevertheless expected that
the amino acid response (AAR) would be activated in the liver. The AAR
is a conserved canonical stress-response pathway that is enacted as a
cytoprotective response to nutrient limitation [16,17,31,32]. AA restric-
tion activates the serine/threonine protein kinase General control
nonrepressed 2 (GCN2) and switches on the AAR initiating a cascade of
events including the phosphorylation of Eukaryotic translation initiation
factor 2A (eIF2a), a common factor in multiple cellular stress-responsepathways that are called the integrated stress response. The phosphory-
lation of eIF2a increases the translation of a subset of mRNAs including
the transcription factor activating transcription factor 4 (ATF4). ATF4 acti-
vates target genes including pseudokinase tribbles homolog 3 (TRB3) and
ATF3, which respond to AA deﬁciencies [33–36]. We found expected al-
terations many genes in this pathway including ATF3, ATF4, ATF5, aspar-
agine synthetase (glutamine-hydrolyzing) (ASNS), and TRB3. Interestingly,
ATF4 regulates FGF21 and this may in part explain FGF21's induction
upon ketogenic diet feeding [25,37]. We also found diminished expres-
sion of the transcript KLF15, which is associated with reduction of
amino acid catabolism pathways as it regulates catabolic processes
through genes encoding the transcripts for ALT1, HPD, and Prodh [38,39].
In humans KD has clinical utility as a therapy for refractory epilepsy
[4,5] and is also used forweight loss [3]. KDhas beenmodeled inmice in
attempts to understand the physiologic states thatmediate both seizure
suppression and weight loss. Previous feeding studies were limited to
3–4months. Furthermore there are concerns about long term consump-
tion of KD because of increased fatty liver and inﬂammation. In this ﬁrst
life-long KD feeding study, we found that the diet waswell tolerated, as
mice had normal life expectancy andmedian life span. Mice consuming
KD remained lighter and had a higher relative lean body mass. The KD
cohorts remainedmore responsive to insulin and glucose tolerant at ad-
vanced ages of 60weeks. The low carb content of the diet, especially the
absence of sugars may also contribute to the improved glucose and de-
creased insulin. Gene expression and metabolomic analysis revealed
Fig. 7. Low AA availability leads to a hepatic amino acid response and down-regulation of hepatic amino acid catabolism. Mice eating KD consumed 5–30%/daily of the AA of the mice on
chow [levels in brackets], yet despite this lowAA availability circulating levels of AA are largelymaintained (A). Hepatic gene expression: Increases in amino acid response genemarkers in
KD-fed mice. ATF3, ATF4, ATF5, activating transcription factor 3,4,5, ASNS, asparagine synthetase (glutamine-hydrolyzing), TRB3, tribbles homolog 3 (B). Hepatic amino acid catabolism
genes are decreased in KD samples suggesting protection of amino acid content. ALT1, glutamic-pyruvate transaminase (alanine aminotransferase); HPD, 4-hydroxyphenylpyruvate
dioxygenase; Prodh, proline dehydrogenase (oxidase) 1; Bckdk, branched chain ketoacid dehydrogenase kinase; KLF15, Krüppel-like factor 15 (C). Data is shown as means ± SEM.
Two-way ANOVA utilized on hepatic gene expression, effects of duration and diet queried, post-hoc comparisons determined by Sidak's post-hoc test for individual time point analysis,
signiﬁcance (P b 0.05) is designated by letters: asigniﬁcantly different from STCH; bsigniﬁcantly different from LTCH; csigniﬁcantly different from STKD; dsigniﬁcant effect of diet; and
esigniﬁcant effect of age. ND= none detected. Gene expression: n= 5–9 per group.
2064 N. Douris et al. / Biochimica et Biophysica Acta 1852 (2015) 2056–2065sustained changes in critical metabolic regulators including compensa-
tory responses in amino acid metabolism, possibly due to chronic acti-
vation of the amino acid starvation response. All of these metabolic
adaptations likely contribute to the fact that the diet is well-tolerated
long-term. Diet studies in mice, including longevity studies, are held in
conditions of standard laboratory housing that typically lack access to
exercise and enrichment. Such enhancements may alter the degree of
stress in mice and could change morbidity/mortality and should be
evaluated in less stressful environments in the future as these might
also impart an increase in inﬂammatory and ﬁbrosis markers.
Understanding the ketotic state is of signiﬁcance consequence with
wide implications for the patients who depend on this diet for various
therapies. In addition, a recent report highlighted the important role of
ketogenesis as a critical regulator in hepatic metabolism to prevent
diet-induced fatty liver disease and hyperglycemia [40]. Further inquiry
into the metabolic ﬂux brought on by ketogenesis is important and
should reveal valuable contributions to the understanding ofmetabolism.
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